Next-generation Sequencing Library Preparation Market (By Sequencing Type: Targeted Genome Sequencing, Whole Genome Sequencing; By Product; By Application; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The global next-generation sequencing library preparation market was surpassed at USD 1.44 billion in 2022 and is expected to hit around USD 4.93 billion by 2032, growing at a CAGR of 13.09% from 2023 to 2032.

Report Highlights

  • The targeted sequencing held the largest share in 2022. 
  • The reagents & consumables held the largest share of 77.2% in 2022. 
  • The drug & biomarker discovery held the largest share of 62.26% in 2022. 
  • The academics & research institutions segment held the highest market share in 2022. 
  • North America leads the global NGS library preparation market with a share of 48.99% in 2022. 

Numerous market players offer a broad spectrum of solutions for NGS library preparation to suit the specific requirements of NGS-based analysis.

Advancements in sequencing technology boost the demand for disease panels. NGS libraries are prepared by using nucleotide amplification and sequencing of a specific gene that is causative of a disease condition. The disease diagnosis panels are precisely designed to analyze specific genetic characteristics of a disease condition. For instance, in February 2022, the OncoDNA introduced OncoDEEP kit for analysis of translocations, somatic variants, genomic signatures and predictive biomarkers to aid cancer therapy. The kit also effectively measures tumor mutational burden, microsatellite instability, and loss of heterozygosity.

The COVID-19 pandemic had a significant impact on the adoption of sequencing technology for metagenomics and diagnostics. Furthermore, several key players launched their NGS-based diagnostic tests for COVID-19 and other viral infections. For instance, in April 2021, QIAGEN N.V. released its first-ever QIAseq SARS-CoV-2 diagnostic kit, to be used for the enrichment of the COVID-19 genome and library preparation solution to yield a sequence of the SARS-CoV-2 genome.

Moreover, the growing incidence of diseases and the demand for novel drug discovery, collectively foster the growth of the market. For instance, in September 2022, IDT launches an NGS library preparation solution, xGen monkeypox virus amplicon panel for the precise detection of monkeypox viral infection by genotyping using viral DNA by construction of an NGS library.

Whole-Exome Sequencing is essentially used for the detection of rare genetic disorders by detecting expressive biomarkers that feature mutations, that are causative of various disease conditions. Further, the Whole-Genome Sequencing (WGS) is used for the detection of novel genetic mutations in rare diseases. For instance, in January 2022, researchers at the University of Stanford secured a first-ever Guinness record for a sequencing technique by sequencing a whole human genome in the least turnaround time with a record diagnostic rate for rare disease diagnosis.

Report Coverage Details
Market Size in 2022 USD 1.44 billion
Revenue Forecast by 2032 USD 4.93 billion
Growth rate from 2023 to 2032 CAGR of 13.09%
Base Year 2022
Forecast Period 2022 to 2032
Segmentation Sequencing type, Product, Application, End-use, Region
Companies Covered Agilent Technologies, Inc., Integrated DNA Technologies, F. Hoffmann-La Roche AG, Inc., Illumina, Inc., Beckman Coulter Inc. (now part of Danaher Corporation), Becton, Merck KGaA, Dickinson and Company, New England Biolabs, Inc., PerkinElmer Inc., QIAGEN N.V., Pacific Biosciences of California, Inc., Thermo Fisher Scientific Inc., Tecan Group Ltd.

 

Sequencing Type Insights

The targeted sequencing held the largest share in 2022. Targeted sequencing using facilitates robust detection of commonly occurring and rare genetic variations that may be causative of a disease condition. It is also used for the detection of genetic aberrations that are contributive to therapeutic drug response and adverse effects in an individual. The growing global incidence of diseases and genetic disorders including cancers are contributing to the growth of the segment.

The WGS segment is anticipated to grow significantly during the forecast period. Lowered sequencing costs and analysis of genome-wide characteristics make whole-genome sequencing a powerful tool for genomics research. It is a comprehensive technique that is used for analysis of entire genome for detailed inference of inherited disorders, characterizing mutations and to trace disease outbreaks. For instance, In December 2021, PacBio signed into a collaboration with researchers at UCLA for advanced identification of the causes of rare diseases. The collaboration is intended to leverage PacBio’s Hi-Fi long-read sequencing technology for WGS to analyze undiagnosed pediatric rare diseases.

Products Insights

The reagents & consumables held the largest share of 77.2% in 2022. NGS library preparation includes the construction of DNA and RNA sequence libraries, amplification, and quantification. Many players are collaboratively working towards the construction of specific libraries to yield the most favorable outcomes from sequencing, using appropriate laboratory reagents. For instance, in January 2022, Singular Genomics Systems, Inc. signed into a collaboration with Watchmaker Genomics to aid researchers and clinicians to validate its Watchmaker-DNA library preparation kits to be used with the G4 sequencing platform using NGS and multiomics technologies.

The instrument segment is anticipated to show a significant market share in 2022. The ability to produce huge data with sequencing makes WGS a powerful tool for genomics research. Moreover, the introduction of advanced and novel sequencing instruments boosted segment growth. For instance, in December 2022, Singular Genomics introduced the G4 Sequencing platform. This novel platform will offer adjustable run capacity and up to three times the data output per hour of existing benchtop instruments.

Application Insights

The drug & biomarker discovery held the largest share of 62.26% in 2022. Many companies are collaboratively working towards construction of precise NGS libraries yield most favorable outcomes from sequencing, using appropriate laboratory reagents. For instance, in September 2022, QIAGEN entered into a collaboration with Neuron23 for the development of NGS-based companion diagnostics using Neuron23’s proprietary molecule, leucine-rich repeat kinase inhibitor which is a brain penetrant used for the treatment of Parkinson’s disease. Qiagen will develop and validate a clinical trial assay that will essentially identify the combination of biomarkers identified by Neuron23 along with comprehensive support for drug development.

The disease diagnostics segment is anticipated to grow significantly during the forecast period. NGS reliably sequences all genes that are relevant to a given phenotype to precisely detect the causative contribution to a disease condition. Moreover, NGS performs simultaneous analysis of multiple genes potentially saving time, money, and tissue if many potential markers are needed to be analyzed for a disease. For instance, in November 2022, Illumina Inc. declares the release of a novel NGS-based diagnostic test for the identification of genito-urinary pathogens and antimicrobial resistance using precision metagenomics for the detection and quantification of over 170 pathogens and more than 3700 markers associated with 18 different drug classes.

End-use Insights

The academics & research institutions segment held the highest market share in 2022. NGS based high-throughput sequencing technologies have been extensively applied in specific research activities like gene-expression profiling, chromatin immune-precipitation and small-RNA sequencing to enhance the outcomes of biological and biomedical research. For instance, in March 2021, researchers at the University of California signed into a collaboration with Miroculus, Inc., and Purigen Biosystems, for the development of a revolutionary tool for personal lab automation for the optimization of an automated PCR-free Whole Genome Sequencing library preparation workflow with micro-input human samples.

The Hospital & Clinics segment is anticipated to grow significantly during the forecast period owing to the rising incidence of cancer, genetic disorders, and rare diseases across the globe. According to the Centre for Disease Control (CDC), NGS has transitioned from research to clinical use in the past 5 years. Genome sequencing analysis is a preferred diagnostic step because its outcomes offer insights into the characteristic contribution of genes to cause a given disease condition.

Regional Insights

North America leads the global NGS library preparation market with a share of 48.99% in 2022. The growth of the market in the region is mainly attributed to extensive disease-based research studies sponsored by academic research institutes and pharmaceutical giants. For instance, in March 2021, Swift Biosciences signed into a collaboration with SPT Labtech for enhancement of Swift Biosciences' library preparation kits on mosquito genomics and dragonfly discovery platforms, so as to expand the portfolio of library preparation solutions for degraded DNA, low input RNA and custom amplicon panels.

The Asia Pacific is expected to grow considerably in the future due to the rising prevalence of rare diseases and high population density. Moreover, key market players are working towards entering the Asia Pacific market with their NGS library preparation expertise. For instance, in May 2021, BGI signed into an agreement with Ethiopian Biotechnology Institute to carryout pilot scale testing of HPV genotyping to establish a novel technique for HPV screening, diagnosis, and treatment.

Key Players

  • Agilent Technologies, Inc.
  • Integrated DNA Technologies
  • F. Hoffmann-La Roche AG, Inc.
  • Illumina, Inc.
  • Beckman Coulter Inc. (Danaher Corporation)
  • Becton
  • Merck KGaA
  • Dickinson and Company
  • New England Biolabs Inc.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Pacific Biosciences of California, Inc.
  • Thermo Fisher Scientific Inc.
  • Tecan Group Ltd.

Market Segmentation

  • By Sequencing Type Outlook
    • Targeted Genome Sequencing
    • Whole Genome Sequencing
    • Whole Exome Sequencing
    • Other Sequencing Types
  • By Products Outlook
    • Reagents & Consumables
      • DNA Library Preparation Kits
      • Library Preparation Kits
      • RNA Library Preparation Kits
      • Other Reagents & Consumables
    • Instruments
  • By Application Outlook
    • Drug & Biomarker Discovery
    • Disease Diagnostics
      • Cancer Diagnostics
      • Reproductive Health Diagnostics
      • Infectious Disease Diagnostics
      • Other Disease Diagnostic Applications
    • Others
  • By End-use Outlook
    • Hospitals and Clinics
    • Academic and Research Institutions
    • Pharmaceutical and Biotechnology Companies
    • Others
  • By Regional Outlook
    • North America
      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Russia
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Australia
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East and Africa (MEA)
      • South Africa
      • Saudi Arabia
      • UAE

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers